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Abstract
Background: There is a need for effective drugs in the prevention and treatment of heterotopic ossifications (HO)
after fractures. Echinomycin has been shown to prevent formation of HO in an animal model. However, before it
may be considered as an option against HO, it needs to be studied whether it prevents fracture healing similar to
non-steroidal anti-inflammatory drugs (NSAIDS). Therefore, the hypothesis was that echinomycin prevents fracture
healing and callus formation.
Methods: In an experimental murine pilot study, standard blunt femur fractures were induced and retrograde
intramedullary compression fixation of the femur was performed. The treatment group (n = 8) received echinomycin
(0.3 mg/kg body weight) and the control group (n = 8) did not receive echinomycin. The fractures and implant positions
were verified by conventional X-rays immediately postoperatively. As the primary outcome variable, fracture healing
(osseous consolidation) was evaluated by conventional X-rays and micro-computed tomography (CT) scans after ten
weeks and graded as healed, partial or complete pseudarthrosis. The secondary outcome, callus formation, was graded
semi-quantitatively from 0 (mostly absent) to 3 (maximum).
Results: Fracture healing was present in all living cases after ten weeks concerning the treatment group. Partial
pseudarthrosis was seen in two cases, one in the treatment and another one in the control group. Complete
pseudarthrosis was seen in one case of the control group after an open fracture. Callus formation was similar in
both groups with a mean grade of 1.5 within each group. Two cases of the treatment group died.
Conclusion: As a novel finding, echinomycin did not inhibit fracture healing or callus formation in this in vivo murine
standard femur fracture model pilot study. Further studies involving a larger number of cases, quantitative assessment
with CT scans and histopathological analysis are needed before generalizing the results of this pilot study.
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Background
Heterotopic ossifications (HO) are characterized by
pathologic bone formation outside of osseous tissue.
The origins of HO are found in traumatic, neurogenic
or genetic reasons. Traumatic etiologies involve fractures,
brain injuries and burns. Thus, HO are commonly
encountered by orthopedic trauma surgeons [1–3]. The
exact pathogenic mechanism is not yet fully understood.
Hypoxic stress may activate the deoxyribonucleic acid-
(DNA-)binding activity of hypoxia-inducible factors (HIF)
[4]. This may induce angiogenic stimulators, leading to
the activation of vascular endothelial growth factor
(VEGF) [5] and osteoprogenitor cells [6]. Vascular
endothelial growth factor leads to the formation of
endothelial cells and osteoprogenitor cells differentiate
from mesenchymal stem cells via chondrocytes into
osteoblasts. In comparison to normal callus formation,
these events ultimately lead to the deposition of calcium
and formation of HO [7].
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Thus far, non-steroidal anti-inflammatory drugs
(NSAIDS) are most commonly used drug for HO,
while radiotherapy is a less commonly used option
and bisphosphonates have fallen out of favor [7]. How-
ever, they do not halt the formation of HO completely,
are accompanied by serious adverse effects [8, 9], and,
importantly, inhibit fracture healing [10–14]. So far,
surgical removal constitutes the only genuine treat-
ment option for HO. However, the nature of an inva-
sive procedure with its accompanied risks such as
nerve lesions and, particularly, high recurrence rate
remain an ongoing dilemma for doctors and patients
alike. Therefore, there is an increasing need for the
use of therapeutic agents in the prevention and treat-
ment of HO [15].
Echinomycin is a cyclic peptide metabolite from
Streptomyces species MST-AS5446 and acts as an
antibiotic agent [16]. It belongs to the quinoxalines
and has been attributed similar effects to vancomycin
[17]. It is able to inhibit HIF1-alpha (α) through DNA
intercalation [18]. This is important in cellular mecha-
nisms of tumor hypoxia [19]. So far, there is only one
recent study [1] that has linked echinomycin to HO. It
was shown that echinomycin effectively prevents for-
mation of HO in a murine model. This is most likely
caused by interruption of inductive signaling pathways
of hypoxia, HIF1-α, VEGF, and angiogenesis. If it can
be demonstrated that echinomycin does not inhibit
fracture healing and does not lead to an increased rate
of pseudarthrosis [20–22], it may potentially become
of interest for clinicians.
It remains unclear whether echinomycin can be suc-
cessfully used in the prevention of HO after fracutres
since there are no studies on the potential adverse effect
of echinomycin on fracture healing and callus formation
as seen with NSAIDS. Therefore, the hypothesis of this
experimental animal pilot study was that echinomycin
prevents fracture healing and callus formation.
Methods
The experimental protocols were approved by the local in-
stitutional review committee (cantonal veterinary office)
and met the guidelines of the local governmental agency.
Animals
This study included cluster of differentiation-1 (CD1)
mice because they are not genetically modified, rather
large and bred locally [1]. Male mice were used because
human HO formation is more pronounced in males.
Mice were marked on the tail for identification. Isoflur-
ane 2–5 % in oxygen (flow rate 400 milliliter/minute (ml/
min)) via nose cone was used for anesthesia. Buprenor-
phine (0.05 mg/kg) was administered subcutaneously for
intraoperative pain management and paracetamol
(syrup 3 %, 200 milligram/kilogram (mg/kg)) was pro-
vided for 1–3 postoperative days. Mice were followed
up and monitored several times a day. A score-sheet
was used in order to detect any signs of distress (shiver-
ing, apathy, no water or food intake). No signs of in-
creased distress were noted and treatment with
paracetamol did not have to be extended.
Surgery
Retrograde intramedullary compression fixation of the
femur through a knee arthrotomy approach was chosen
because this method allows mice to fully ambulate after
surgery [23]. A five mm incision was used for a parape-
tallar approach. The patella was luxated laterally. A 0.5
drill bit was used for intercondylar opening of the medul-
lary cavity. A guide wire (d = 0.2 mm) was used to assem-
ble the needle tip (25 G force (G) x 16 mm, d = 0.55 mm)
for intramedullary reaming up to the proximal femur in
the area of the trochanter. The needle tip was removed
while keeping the guide wire in place. Using the guide
wire, the Association for the Study of Internal Fix-
ation (AO) MouseScrew (AO foundation, Davos,
Switzerland) was assembled and carefully inserted until
the tip approached the area of the trochanter. Clockwise
turning of the MouseScrew was initiated to secure the tip
in the cortical bone. The patella was repositioned and
refixated, and the wound was closed with Prolene Poly-
propylene Suture 7.0 (Ethicon Incorporation, Johnson and
Johnson, New Brunswick, New Jersey, United States).
Fracture model
There are open and closed standard fracture models
[23–28]. Open models use osteotomies whereas closed
models utilize three-point bending or drop weight. Using
an established closed standard fracture model, femur
fractures can be induced through a tower with a drop
weight [24–26]. These fractures could be induced after
performing intramedullary fixation with a pin. In mice,
open osteotomies [27] or three-point fracturing devices
can also be used [28]. In this murine study, a standard
blunt femur fracture was induced by a fracture device
(AO foundation, Davos, Switzerland) consisting of a
tower with a drop weight resulting in 500 G from 35 cen-
timeters (cm), theoretically leading to 0.5 shaft dislocation,
as previously described (Figs. 1, 2, and 3) [24].
Fig. 1 Lateral X-ray of the intramedullary compressed femur immediately
postoperatively
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Groups
Mice (cases) were randomly assigned to one of two
groups. The treatment (echinomycin [E]) group included
eight cases (n = 8, E.1 - E.8) and the control (C) group
included another eight cases (n = 8, C.1 - C.8). The treat-
ment group received echinomycin (10 microgram (mcg)
[0.3 mg/kg body weight]) (Sigma-Aldrich, Buchs,
Switzerland). Echinomycin was diluted in dimethyl sulfox-
ide (DMSO) and administered subcutaneously in the
interscapular region. Injections were performed once a
week for a total amount of four weeks [1]. The dosage was
chosen due to the following considerations. A previous in
vitro study [16] reported that the lethal dose 50 (LD50) of
echinomycin was 12.3 mg/kg. However, further in vitro
murine studies [29, 30] have used higher dosages of
10 mg/kg every two days for 14 days [29] and up to
40 mg/kg every two days for a total of five administrations
[30] without reporting adverse effects. Since Zimmermann
et al. [1] reported an effect of echinomycin on heterotopic
ossification without observing any adverse or lethal ef-
fects, the same dosage was used in this study. Euthanasia
and harvesting of the limbs were performed at ten weeks.
Radiologic assessment
The fractures and implant positions were verified by
conventional X-rays (Fluoroscan InSight, Hologic In-
corporation, Bedford, Massachusetts, United States)
immediately postoperatively (Fig. 1). After ten weeks,
the harvested legs underwent a second conventional radio-
logic work-up (Philips Allura FD20, Koninklijke Philips
Electronics Naamloze Vennootschap, Amsterdam, The
Netherlands) and micro-computed tomography (CT)
(nominal resolution of 30 mm, b-cube, Swiss Federal
Institute of Technology, Zurich, Switzerland) with par-
ticular focus on fracture healing and callus formation
(Figs. 2 and 3). The primary outcome, fracture healing
was assumed with osseous consolidation of both cortices.
Partial pseudarthrosis was determined as osseous consoli-
dation of only one cortex and complete pseudarthrosis
was presumed without osseous consolidation of either
cortex. The secondary outcome, callus formation was
graded semiquantitatively with a score from 0–3 (0 =
mostly absent, 1 =minimum, 2 =medium and 3 =max-
imum). Radiography and micro-CTs were scored by two
independent investigators. Descriptive analyses were per-
formed (Table 1).
Results
Mice
Two cases of the treatment group died. One death occurred
intraoperatively, most likely due to cardiopulmonary arrest.
Another death occurred about one week postoperatively
Fig. 2 Lateral X-ray of the intramedullary compressed femur ten
weeks postoperatively
Fig. 3 Coronal plane of a micro-computed tomography scan of the
intramedullary compressed femur ten weeks postoperatively
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due to unknown reasons. The remaining cases were able to
ambulate well postoperatively. No other adverse effects
were observed with administration of echinomycin.
Fracture healing
Using a micro CT, osseous consolidation and fracture
healing was observed in all (100 %) cases alive after
10 weeks in both groups (Figs. 2 and 3 and Table 1). Par-
tial pseudarthrosis was seen in two cases: one (12.5 %) in
the treatment and another one (12.5 %) in the control
group. Complete pseudarthrosis was seen in one
(12.5 %) case of the control group after an open fracture.
The open fractures (12.5 % each) had occurred acciden-
tally from the drop weight. Inadvertent implant bending
was seen immediately postoperatively in three cases.
Two (25 %) cases of the treatment group and one
(12.5 %) case of the control group were affected.
Callus formation
Callus formation was similar in both groups. The mean
grade of callus formation was 1.5 within each group.
Using micro-CT, some callus formation was visible in all
(100 %) cases alive after 10 weeks indicating that the
femoral fracture model resulted in an actual fracture in
every (100 %) case.
Discussion
This pilot study represents the first investigation about
the effects of echinomycin on fracture healing and callus
formation. According to the results, echinomycin does
not inhibit bone healing or callus formation in a murine
fracture model. This lowers the concern that echinomycin
may compromise fracture healing and callus formation by
blocking HIF1-α. Therefore, valuable information is added
on the recently introduced idea that echinomycin may be
an effective drug in the management of HO [1].
Echinomycin, an antibiotic agent inhibiting HIF1-α, has
recently [1] been shown in the successful prevention of
HO. In a study by Zimmermann et al. [1], the effect of echi-
nomycin on formation of HO was examined in a murine
Achilles tendon tenotomy model. Analysis with micro-CT
and histology showed that echinomycin effectively reduced
formation of HO in a murine model. This effect was most
likely attributed to the interruption of inductive signaling
pathways of hypoxia, HIF1-α, VEGF, and angiogenesis.
These findings have led to the presented study because it is
necessary to investigate the effects of echinomycin on frac-
ture healing and callus formation before it can be used in
the prevention of HO in a clinical setting.
The presented results add information to the current
literature because the use of NSAIDS in HO has been
limited due to their adverse effects and inhibition of
fracture healing [10]. Adverse effects include gastrointes-
tinal bleeding [8] and nephrotoxicity [9]. There are sev-
eral studies [10–13] about the inhibition of fracture
healing of NSAIDS. For example, Giannoudis et al. [13]
compared 32 patients with nonunion of the femur to
healed fractures and found a significant association be-
tween nonunion and the use of NSAIDS. Similarly, Burd
et al. [10] reported an increased nonunion rate of 26 % in
patients receiving indomethacin compared to 7 % in pa-
tients without indomethacin when looking at 282 patients
with an acetabular fracture. This may be based on the fact
that osseous consolidation requires an initial phase of in-
flammation, which is inhibited by NSAIDS [11]. More
precisely, NSAIDS inhibit bone regeneration by inhibiting
cyclooxygenase activity leading to a decrease in lipid me-
diators such as omega-(Ω-)6 fatty acids including arachi-
donic acid and Ω-3 fatty acids that are involved in cell
signaling. The differentiation of mesenchymal cells into
osteogenic cells is repressed [7]. This ultimately inhibits
bone healing [12]. The presented results suggest that echi-
nomycin may not be accompanied by these limiting factors.
Secondary bone healing with some callus formation
was seen in all cases even though fractures were difficult
to identify on the immediate postoperative X-rays [14].
The partial pseudarthrosis rate, which is known from
Table 1 Fracture healing, callus formation, and complications
are shown for mice in the treatment (E.1 – E.8) and control
(C.1 – C.8) groups
Group Fracture
healing
Callus formation
(0 =mostly absent, 1 =minimum,
2 =medium, 3 =maximum)
Complications
E.1 Yes 2 Implant bending
E.2 Yes 2 No
E.3 Yes 1 Implant bending,
partial pseudarthrosis
E.4 Yes 2 No
E.5 Yes 1 No
E.6 Yes 1 No
E.7 NA NA Died intraoperatively
E.8 NA NA Died one week
postoperatively
C.1 Yes 1 Partial pseudarthrosis
C.2 Yes 3 No
C.3 Yes 2 No
C.4 No 0 Implant bending,
open fracture,
complete
pseudarthrosis
C.5 Yes 2 No
C.6 Yes 1 No
C.7 Yes 1 No
C.8 Yes 2 No
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humans [20], was low and one complete pseudarthrosis
was most likely due to an accidental open fracture [21, 22].
It remains difficult to differentiate HO from physiologic
callus formation in fractures histologically [15] and the
reason for the appearance of HO without simultaneous
callus formation is still debated [4, 6]. It has to be
assumed that HO is formed in hypoxic soft tissue
through activation of HIF and VEGF, while callus is
formed around bone with normal oxygen supply. This can
be exemplified by study by Rath et al. [4], who showed
that HO formation could be decreased by resection of
necrotic gluteus minimus muscle. In comparison to callus
formation, HO also lacks periosteum [7].
The rather low dose (0.3 mg/kg body weight) of echi-
nomycin was chosen to avoid possible adverse effects
[1]. Even though two mice died, one death was probably
attributed to cardiopulmonary arrest intraoperatively,
while the other death remains unknown. However, in a
previous human colon cancer cell line study by Park et al.
[16], the lethal dose 50 (LD50) was 12.3 mg/kg body
weight, which is much higher than the dose used in our
study. Since Zimmermann et al. [1] did not report any
adverse effects with the same dose, the cause of death is
unlikely to be caused by echinomycin.
This murine standard fracture model of this study,
which used a tower with a drop weight after intramedul-
lary fixation prior to inducing the fracture [26], was able
to produce fractures in all cases and provided consistent
results comparable to other fracture models such as
open osteotomy or closed three-point bending [31]. The
drop weight resulted in implant bending in three cases
and an open fracture in one case. These results add
valuable information about the use of fracture models in
mice [24, 26, 31]. Since the effect of echinomycin on
HO has only been studied in mice, an easy-to-use stand-
ard closed femur fracture model with a drop weight was
chosen in mice. In mice, potential gene defects in knock-
out strains may also be evaluated [32].
As a limitation, this study included a small sample size
of eight cases in each group. Therefore, no power or num-
ber needed to treat analysis was performed and results
need to be interpreted with care. The relatively low dose
of echinomycin was chosen due to the aforementioned
considerations, but may be further investigated in the fu-
ture. Nonetheless, the results of the presented pilot study
are pointing toward an interesting direction for potential
future studies of this clinically relevant topic. Regularly
spaced radiological examinations were avoided because
radiation may interfere with HO [2, 3]. The use of CT
scans, at least for final examinations, may be preferred
because fractures are difficult to identify on conven-
tional X-rays. These CT scans may also be used to
quantitatively assess bone formation, which was not the
subject of the present study. In this study, histological
evaluation was not pursued. Thus, there is a potential
for future studies involving a larger experimental sam-
ple size to draw statistically relevant conclusions and
histological assessments in order to quantify osseous
consolidation more precisely. It also seems plausible to
perform experimental studies with regard to the correct
dose and specific effects of echinomycin. If it was to be
shown that echinomycin could be used as a regular
pre- or postoperative antibiotic, it may ultimately be-
come an option in the perioperative period in patients
at risk for HO.
Conclusion
This is the first study to investigate the effects of echino-
mycin on fracture healing and callus formation. Echino-
mycin did not seem to inhibit fracture healing or callus
formation in this vivo pilot study using a murine stand-
ard femur fracture model. Further studies involving a
larger sample size, quantitative assessment with CT
scans and histopathological analysis may provide more
generalizable information.
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